Gland Pharma Limited (GLAND.BO)
INR 1762.35
(-0.09%)
INR 1762.35
(-0.09%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.06 Billion INR | 2745.62% |
| 2022 | 37.44 Million INR | -16.47% |
| 2021 | 44.82 Million INR | -4.6% |
| 2020 | 46.98 Million INR | -5.93% |
| 2019 | 49.94 Million INR | -16.92% |
| 2018 | 60.11 Million INR | -9.34% |
| 2017 | 66.3 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 936.17 Million INR | 0.0% |
| 2023 Q2 | 1.47 Billion INR | 0.0% |
| 2023 FY | 1.06 Billion INR | 2745.62% |
| 2023 Q4 | 1.06 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 37.44 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 37.44 Million INR | -16.47% |
| 2022 Q2 | 38.35 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 45.32 Million INR | 0.0% |
| 2021 FY | 44.82 Million INR | -4.6% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 44.82 Million INR | 0.0% |
| 2020 Q4 | 46.98 Million INR | 0.0% |
| 2020 Q1 | 49.94 Million INR | 0.0% |
| 2020 FY | 46.98 Million INR | -5.93% |
| 2019 FY | 49.94 Million INR | -16.92% |
| 2019 Q4 | 49.94 Million INR | 0.0% |
| 2018 FY | 60.11 Million INR | -9.34% |
| 2017 FY | 66.3 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Abbott India Limited | 367.6 Million INR | -189.826% |
| Cipla Limited | 2.25 Billion INR | 52.737% |
| GlaxoSmithKline Pharmaceuticals Limited | 64.69 Million INR | -1546.906% |
| Kopran Limited | 166.02 Million INR | -541.703% |
| Marksans Pharma Limited | 1.9 Billion INR | 43.932% |
| NGL Fine-Chem Limited | 7.44 Million INR | -14204.511% |
| Pfizer Limited | 543.5 Million INR | -96.026% |
| Sanofi India Limited | 139 Million INR | -666.475% |
| SMS Pharmaceuticals Limited | 1.22 Billion INR | 12.734% |